BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31253381)

  • 1. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.
    Katzmann JA; Willrich MA; Kohlhagen MC; Kyle RA; Murray DL; Snyder MR; Rajkumar SV; Dispenzieri A
    Clin Chem; 2015 Feb; 61(2):360-7. PubMed ID: 25451866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
    Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
    Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
    Chae H; Han E; Yoo J; Lee J; Lee JJ; Cha K; Kim M; Kim Y; Lee SE; Min CK
    Clin Chim Acta; 2018 Apr; 479():7-13. PubMed ID: 29324245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
    Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
    Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
    Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
    Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical validation of the Hevylite assays for M-protein quantification.
    Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
    Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].
    Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy.
    Wolff F; Debaugnies F; Rozen L; Willems D; Brohet F; Brauner J; Stordeur P
    Clin Biochem; 2013 Jan; 46(1-2):79-84. PubMed ID: 23041246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
    Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
    Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
    Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
    Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.